BioVie Inc (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for liver disease and neurological disorders, closed a public offering of 15M common shares, 6M pre-funded warrants, and warrants for 10.5M common shares at $1.00 each. With gross proceeds of approximately $21M, the company plans to utilize the funds for working capital and general corporate purposes.
Advertisement Go to Proactive UK Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Advertisement Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com